| DC Field | Value | Language |
| dc.contributor.author | Secu, Doina | - |
| dc.contributor.author | Blăniță, Daniela | - |
| dc.contributor.author | Ușurelu, Natalia | - |
| dc.contributor.author | Sacară, Victoria | - |
| dc.date.accessioned | 2026-09-16T12:24:12Z | - |
| dc.date.available | 2026-09-16T12:24:12Z | - |
| dc.date.issued | 2026 | - |
| dc.identifier.citation | SECU, Doina; Daniela BLĂNIȚĂ; Natalia UȘURELU and Victoria SACARĂ. The phenotypic and molecular spectrum of pediatric patients with mitochondrial involvement. In: Conferinţă internaţională "Pediatria fără frontiere", 19-20 iunie 2026. Ediția 2/ sub redacţia: Svetlana Şciuca. Chişinău : [s. n.], 2026, pp. 205-215. ISBN 978-5-85748-419-7. | en_US |
| dc.identifier.isbn | 978-5-85748-419-7 | - |
| dc.identifier.uri | https://repository.usmf.md/handle/20.500.12710/33641 | - |
| dc.description.abstract | Abstract
Introduction: Mitochondrial disorders exhibit unparalleled clinical and genetic
complexity due to dual-genomic control, typically manifesting in pediatric populations
with an ultra-rapid, multi-systemic progression that challenges conventional diagnostic
boundaries. This study evaluates the phenotypic and molecular spectrum of 39
predominantly pediatric patients with mitochondrial involvement, identified from a
broader multi-systemic referral cohort of 240 children.
Materials and Methods: Primary enrollment comprised patients achieving a
modified Nijmegen Mitochondrial Disease Score (NMDS) ≥ 3. The dual-genomic
workflow paired peripheral blood quantitative PCR-high resolution melting screening
with targeted mitochondrial DNA sequencing, real-time qPCR for quantitative copy
number evaluation, and high-throughput nuclear genomic analysis. Clinical, metabolic,
instrumental and neuroimaging parameters were cross-linked using a Spearman
correlation matrix.
Results: The cohort exhibited a highly intricate neurodevelopmental and systemic
phenotype, prominently dominated by pervasive multi-organ involvement (87.2%),
seizures (69.2%), brainstem involvement (43.6%), and marked neuromuscular
dysfunction (41.0%). Biochemical profiling confirmed systemic metabolic disruption,
primarily presenting as hyperlactatemia (89.7%) and hyperalaninemia (38.5%).
Instrumental and neuroimaging assessments revealed abnormal neuroradiological
(74.4%), electroencephalographic (53.8%), and electrocardiographic (30.8%) profiles.
Spearman correlation analysis demonstrated that target group status was strongly
anchored by hyperlactatemia (ρ = 0.40) and hyperalaninemia (ρ = 0.38), clustering
tightly (ρ ≈ 0.26) with basal ganglia anomalies, neuromuscular dysfunction, and
developmental regression.
Conclusions: This study demonstrates that an integrated, multi-tiered genomic
workflow successfully identifies relevant genetic variants across both the mitochondrial
and nuclear genomes in 16.3% of cases within a complex screening pool. Pairing a
modified clinical scoring system and core metabolic biomarkers with key neuroimaging
findings establishes a dependable framework for identifying high-probability cases. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Academia de Ştiinţe a Moldovei, Ministerul Sănătăţii al Republicii Moldova, Universitatea de Stat de Medicină şi Farmacie "Nicolae Testemiţanu", Institutul Mamei şi Copilului | en_US |
| dc.relation.ispartof | Conferinţă internaţională "Pediatria fără frontiere", 19-20 iunie 2026. Ediția 2, Chișinău, Republica Moldova | en_US |
| dc.subject | pediatric mitochondrial disease | en_US |
| dc.subject | modified Nijmegen Mitochondrial Disease Score | en_US |
| dc.subject | qPCR-HRM | en_US |
| dc.subject | mtDNA Sanger sequencing | en_US |
| dc.title | The phenotypic and molecular spectrum of pediatric patients with mitochondrial involvement | en_US |
| dc.type | Article | en_US |
| Appears in Collections: | Conferinţă internaţională "Pediatria fără frontiere", 19-20 iunie 2026. Ed. 2: [rezumate]
|